Kite Pharma is currently the only company with two approved CAR T products across five different indications¹ ². Learn more on YESCARTA® and TECARTUS® below!
References
- Yescarta SmPC
- Tecartus SmPC
AXICABTAGENE CILOLEUCEL
Yescarta®
Latest EMA approval: Yescarta in 2L DLBCL
In November 2022, EMA approved Yescarta for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Yescarta in 3L DLBCL and PMBCL
Already 5-year OS follow-up data available for Yescarta in 3L DLBCL and PMBCL.
Yescarta in 4L FL
Efficacy and safety of Yescarta has also been demonstrated in ZUMA-5 study with follicular lymphoma patients
BREXUCABTAGENE AUTOLEUCEL
Tecartus®
Tecartus in Mantle Cell Lymphoma
First CAR T therapy approved for the treatment of mantle cell lymphoma. Study the efficacy and safety of Tecartus.
Tecartus in adult Acute Lymphoblastic Leukaemia
Since September 2022, Tecartus is also approved for the treatment of adult patients 26 years of age and above with relapsed or refractary B-cell precursor acute lymphoblastic leukaemia (ALL).
SE-TEC-0041 | 09/2024
QUESTIONS ON DATA?
Contact
Our Cell Therapy Account Managers can help you
Related information
The right patient
Discover phases of the CAR T journey and patient characteristics
Authorized treatment centers
Kite CAR T treatments are conducted in authorized treatment centres across Sweden
Kite resources
Materials you need to support you with CAR T practice and referrals, including patient information materials
